Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone - An array comparative genomic hybridization study

Genes Chromosomes and Cancer

Volumn 49, Issue 2, 2010, Pages 132-143

  Niini, Tarja ^a   López Guerrero, José Antonio ^b   Ninomiya, Shinsuke ^a   Guled, Mohamed ^a   Hattinger, Claudia Maria ^c   Michelacci, Francesca ^c   Böhling, Tom ^a   Llombart Bosch, Antonio ^d   Picci, Piero ^c   Serra, Massimo ^c   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CHD1L GENE; CHROMOSOME 10; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 15Q; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 20P; CHROMOSOME 20Q; CHROMOSOME 22Q; CHROMOSOME 4Q; CHROMOSOME 5P; CHROMOSOME 6Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME LOSS; CHROMOSOME XP; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FIBROSARCOMA; GENE; GENE AMPLIFICATION; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; STARD13 GENE;

ADULT; AGED; BONE NEOPLASMS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, X; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; FIBROSARCOMA; GENE AMPLIFICATION; GENE DELETION; HUMANS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 75149141075     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20727     Document Type: Article

References (52)

1. Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, Tas E, Serra M, Tarkkanen M, Knuutila S. 2005. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42:158-163.
2. Bozzi F, Tamborini E, Negri T, Pastore E, Ferrari A, Luksch R, Casanova M, Pierotti MA, Bellani FF, Pilotti S. 2007. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors. Cancer 109:1638-1645.
3. Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. 2005. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 4:1270-1274.
4. Campanacci M. 1999.Bone and Soft Tissue Tumors, 2nd ed. Wien: Springer. 1319 p.
5. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. 2002. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160:1567-1572.
6. DuBois S, Demetri G. 2007. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109:813-819.
7. Entz-Werle N, Marcellin L, Gaub MP, Guerin E, Schneider A, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Jeanne-Pasquier C, Terrier P, Dijoud F, Oudet P, Lutz P, Babin-Boilletot A. 2005. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 23:2248-2255.
8. Entz-Werle N, Gaub MP, Lavaux T, Marcellin L, Metzger N, Marec-Berard P, Schmitt C, Brugiere L, Kalifa C, Tabone MD, Pacquement H, Gentet P, Lutz P, Oudet P, Babin A. 2007. KIT gene in pediatric osteosarcomas: Could it be a new therapeutic target? Int J Cancer 120:2510-2516.
9. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG. 2000. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60:129-133.
10. Fang Y, Guan X, Guo Y, Sham J, Deng M, Liang Q, Li H, Zhang H, Zhou H, Trent J. 2001. Analysis of genetic alterations in primary nasopharyngeal carcinoma by comparative genomic hybridization. Genes Chromosomes Cancer 30:254-260.
11. Fuchs B, Inwards CY, Janknecht R. 2004. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res 10:1344-1353.
12. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra S, Pardo J, Prosper F, de Alava E. 2004. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/ KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 10:751-761.
13. Hallor KH, Heidenblad M, Brosjo O, Mandahl N, Mertens F. 2007. Tiling resolution array comparative genomic hybridization analysis of a fibrosarcoma of bone. Cancer Genet Cytogenet 172:80-83.
14. Hattinger CM, Tarkkanen M, Benini S, Pasello M, Stoico G, Bacchini P, Knuutila S, Scotlandi K, Picci P, Serra M. 2004. Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. Eur J. Cell Biol 83:483-491.
15. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826. Hornick JL, Fletcher CD. 2002. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 117:188-193.
17. Kahn LB, Vigorita V. 2002. Pathology and genetics of tumours of soft tissue and bone. In: Fletcher CDM, Unni KK, Mertens F, editors. World Health Organization Classification of Tumours. Lyon, France: IARC Press. p 289.
18. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S. 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572-577.
19. Kim WY, Sharpless NE. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127:265-275.
20. Larramendy ML, Kaur S, Svarvar C, Bohling T, Knuutila S. 2006. Gene copy number profiling of soft-tissue leiomyosarcomas by array-comparative genomic hybridization. Cancer Genet Cytogenet 169:94-101.
21. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M. 2000. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157:1091-1095.
22. Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R, Rao PH. 2004. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39:11-21.
23. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, Fukuda H, Nakano H, Abe S, Tateishi A, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y, Nakamura M. 1999. Cellretained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35:1089-1093.
24. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. 2005. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA 102:15207-15212.
25. Lopez-Guerrero JA, Lopez-Gines C, Pellin A, Carda C, Llombart-Bosch A. 2004. Deregulation of the G1 to S-phase cell cycle checkpoint is involved in the pathogenesis of human osteosarcoma. Diagn Mol Pathol 13:81-91.
26. Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, Tang DJ, Fu L, Wu Z, Chen M, Fang Y, Guan XY. 2008. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology 47:503-510.
27. Maelandsmo GM, Berner JM, Florenes VA, Forus A, Hovig E, Fodstad O, Myklebost O. 1995. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-Relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 72:393-398.
28. Mairal A, Terrier P, Chibon F, Sastre X, Lecesne A, Aurias A. 1999. Loss of chromosome 13 is the most frequent genomic imbalance in malignant fibrous histiocytomas. A comparative genomic hybridization analysis of a series of 30 cases. Cancer Genet Cytogenet 111:134-138.
29. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC, Rao PH. 2004. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 4:45.
30. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J. 2005. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 65:8085-8089.
31. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namlos HM, Wang J, Kristiansen BE, Myklebost O. 2006. Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas. Cancer Res 66:8984-8993.
32. Miettinen M, Lasota J. 2005. KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 13:205-220.
33. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. 1996. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136-142. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. 1998. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153:159-163.
34. Ohguri T, Hisaoka M, Kawauchi S, Sasaki K, Aoki T, Kanemitsu S, Matsuyama A, Korogi Y, Hashimoto H. 2006. Cytogenetic analysis of myxoid liposarcoma and myxofibrosarcoma by arraybased comparative genomic hybridisation. J Clin Pathol 59:978-983.
35. Orlow I, Drobnjak M, Zhang ZF, Lewis J, Woodruff JM, Brennan MF, Cordon-Cardo C. 1999. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: Effect on survival. J Natl Cancer Inst 91:73-79.
36. Pandita A, Zielenska M, Thorner P, Bayani J, Godbout R, Greenberg M, Squire JA. 1999. Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma. Neoplasia 1:262-275.
37. Patino-Garcia A, Pineiro ES, Diez MZ, Iturriagagoitia LG, Klussmann FA, Ariznabarreta LS. 2003. Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas. J Pediatr Hematol Oncol 25:362-367.
38. Pille JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C, Li H. 2005. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11:267-274.
39. Rozeman LB, Szuhai K, Schrage YM, Rosenberg C, Tanke HJ, Taminiau AH, Cleton-Jansen AM, Bovee JV, Hogendoorn PC. 2006. Array-comparative genomic hybridization of central chondrosarcoma: Identification of ribosomal protein S6 and cyclindependent kinase 4 as candidate target genes for genomic aberrations. Cancer 107:380-388.
40. Sahai E, Marshall CJ. 2002. RHO-GTPases and cancer. Nat Rev Cancer 2:133-142.
41. Scotlandi K, Picci P. 2008. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 20:419-427.
42. Serra M, Scotlandi K, Sollazzo MR, Sarti M, Maurici D, Benini S, Picci P, Bertoni F, Baldini N. 1996. Value of immunohistochemical detection of noncollagenous proteins of bone for diagnosis of bone tumours. Int J Oncol 9:257-261.
43. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe HJ. 1998. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 185:345-351.
44. Simons A, Schepens M, Jeuken J, Sprenger S, van de Zande G, Bjerkehagen B, Forus A, Weibolt V, Molenaar I, van den Berg E, Myklebost O, Bridge J, van Kessel AG, Suijkerbuijk R. 2000. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. Cancer Genet Cytogenet 118:89-98.
45. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M. 2003. High-resolution mapping of amplifi-cations and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 38:215-225.
46. Tamborini E, Bonadiman L, Negri T, Greco A, Staurengo S, Bidoli P, Pastorino U, Pierotti MA, Pilotti S. 2004. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 10:8214-8219.
47. Tarkkanen M, Larramendy ML, Bohling T, Serra M, Hattinger CM, Kivioja A, Elomaa I, Picci P, Knuutila S. 2006. Malignant fibrous histiocytoma of bone: Analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. Eur J Cancer 42:1172-1180.
48. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. 1998. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21:177-184.
49. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. 2000. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120:91-98.
50. Ullmannova V, Popescu NC. 2006. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol 29:1127-1132.
51. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, Ladanyi M. 1999. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80:199-204.
52. Zielenska M, Marrano P, Thorner P, Pei J, Beheshti B, Ho M, Bayani J, Liu Y, Sun BC, Squire JA, Hao XS. 2004. High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res 107:77-82.